Sonoma Pharmaceuticals (SNOA) EBITDA Margin Growth (3y) (2013 - 2026)
Sonoma Pharmaceuticals (SNOA) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 3,556.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,556.00 |
| Mar 31, 2026 | 3,174.00 |
| Dec 31, 2025 | 4,671.00 |
| Sep 30, 2025 | 1,593.00 |
| Jun 30, 2025 | -581.00 |
| Mar 31, 2025 | 11,568.00 |
| Dec 31, 2024 | 408.00 |
| Sep 30, 2024 | 200.00 |
| Jun 30, 2024 | -1,005.00 |
| Mar 31, 2024 | 8,949.00 |
| Dec 31, 2023 | -2,410.00 |
| Sep 30, 2023 | -4,716.00 |
| Jun 30, 2023 | -2,465.00 |
| Mar 31, 2023 | 3,671.00 |
| Dec 31, 2022 | -3,709.00 |
| Sep 30, 2022 | 528.00 |
| Jun 30, 2022 | 1,793.00 |
| Mar 31, 2022 | -7,145.00 |
| Dec 31, 2021 | 1,150.00 |
| Sep 30, 2021 | 2,795.00 |